These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 27708433)
1. Epitomics: IgG-epitome decoding of E6, E7 and L1 proteins from oncogenic human papillomavirus type 58. Xu WX; Wang J; Tang HP; He YP; Zhu QX; Gupta SK; Gu SH; Huang Q; Ji CN; Liu LF; Li GL; Xu CJ; Xie Y Sci Rep; 2016 Oct; 6():34686. PubMed ID: 27708433 [TBL] [Abstract][Full Text] [Related]
2. Epitope delimitation: A new method for defining epitopes of human IgG-reactive antigenic peptides based on rabbit-recognized epitope motifs. Tang HP; He YP; Wang J; Zhan JM; Lian WB; Xue F; Wang L; Li Y; Zhang A; Zhang F; Xu C; Li J; Xu WX J Med Virol; 2024 Jan; 96(1):e29388. PubMed ID: 38235845 [TBL] [Abstract][Full Text] [Related]
3. Designing of Epitope-Focused Vaccine by Targeting E6 and E7 Conserved Protein Sequences: An Immuno-Informatics Approach in Human Papillomavirus 58 Isolates. Sabah SN; Gazi MA; Sthity RA; Husain AB; Quyyum SA; Rahman M; Islam MR Interdiscip Sci; 2018 Jun; 10(2):251-260. PubMed ID: 27640170 [TBL] [Abstract][Full Text] [Related]
4. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749 [TBL] [Abstract][Full Text] [Related]
5. Protein intrinsic disorder and human papillomaviruses: increased amount of disorder in E6 and E7 oncoproteins from high risk HPVs. Uversky VN; Roman A; Oldfield CJ; Dunker AK J Proteome Res; 2006 Aug; 5(8):1829-42. PubMed ID: 16889404 [TBL] [Abstract][Full Text] [Related]
6. [Transformation activity and antigenicity of the human papillomavirus type 58 E6E7 fusion gene mutant]. Wang H; Yu JY; Li L Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):491-6. PubMed ID: 24257298 [TBL] [Abstract][Full Text] [Related]
7. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model. Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055 [TBL] [Abstract][Full Text] [Related]
8. Identification of the impact on T- and B- cell epitopes of human papillomavirus type-16 E6 and E7 variant in Southwest China. Chenzhang Y; Wen Q; Ding X; Cao M; Chen Z; Mu X; Wang T Immunol Lett; 2017 Jan; 181():26-30. PubMed ID: 27693214 [TBL] [Abstract][Full Text] [Related]
9. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405 [TBL] [Abstract][Full Text] [Related]
10. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901 [TBL] [Abstract][Full Text] [Related]
11. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types. Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176 [TBL] [Abstract][Full Text] [Related]
12. Developments in L2-based human papillomavirus (HPV) vaccines. Schellenbacher C; Roden RBS; Kirnbauer R Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616 [TBL] [Abstract][Full Text] [Related]
13. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies. Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978 [TBL] [Abstract][Full Text] [Related]
15. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16. Azoury-Ziadeh R; Herd K; Fernando GJ; Frazer IH; Tindle RW Viral Immunol; 1999; 12(4):297-312. PubMed ID: 10630789 [TBL] [Abstract][Full Text] [Related]
16. [Prediction of B cell epitopes of human papillomavirus type 16 L1 protein]. Wang A; Jiang M; Li N; Zhang G; Qi Y; Liu Y; Xi Y; Zhou J Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Apr; 32(4):442-5. PubMed ID: 27053606 [TBL] [Abstract][Full Text] [Related]
17. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development. Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615 [TBL] [Abstract][Full Text] [Related]
18. Mapping the B cell epitopes within the major capsid protein L1 of human papillomavirus type 16. Wang A; Li N; Zhou J; Chen Y; Jiang M; Qi Y; Liu H; Liu Y; Liu D; Zhao J; Wang Y; Zhang G Int J Biol Macromol; 2018 Oct; 118(Pt A):1354-1361. PubMed ID: 29959021 [TBL] [Abstract][Full Text] [Related]
19. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455 [TBL] [Abstract][Full Text] [Related]
20. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]